RedHill Biopharma Reports 2017 Third Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Redhill Biopharma (RDHL) PT Lowered to $20 at Roth Capital Following 3Q Release
November 14, 2017 7:08 AM ESTRoth Capital lowered its price target on Redhill Biopharma (NASDAQ: RDHL) to $20.00 (from $27.00) while maintaining a Buy rating following the company's 3Q earnings report. RDHL reported revenues of $1.5M versus estimate of $900K. Lower gross margins offset the revenue upside and gross... More
